Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer
This is a prospective, open-label, single arm, non-randomized study of RiMO-301 with hypofractionated radiation and a PD-1 Inhibitor in patients with unresectable, recurrent or metastatic head-neck cancer.
Diagnosis of head-neck cancer that requires palliative radiotherapy [+11]
Have signs or symptoms of end organ failure, major chronic illnesses other than... [+6]